Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Short Interest Down 63.6% in April

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLAGet Rating) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 6,400 shares, a decline of 63.6% from the April 15th total of 17,600 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 25,600 shares, the days-to-cover ratio is presently 0.3 days.

Shares of NASDAQ:AYLA traded down $0.04 on Friday, hitting $2.00. The company had a trading volume of 15,654 shares, compared to its average volume of 37,072. The business has a 50 day moving average of $3.34 and a 200 day moving average of $6.20. Ayala Pharmaceuticals has a 52-week low of $1.97 and a 52-week high of $14.95.

Ayala Pharmaceuticals (NASDAQ:AYLAGet Rating) last released its earnings results on Monday, March 28th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.05). Ayala Pharmaceuticals had a negative return on equity of 95.09% and a negative net margin of 1,148.15%. On average, sell-side analysts anticipate that Ayala Pharmaceuticals will post -2.55 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Morgan Stanley bought a new position in Ayala Pharmaceuticals during the 1st quarter worth approximately $46,000. Citadel Advisors LLC acquired a new stake in shares of Ayala Pharmaceuticals during the 2nd quarter worth approximately $107,000. DLD Asset Management LP raised its position in shares of Ayala Pharmaceuticals by 9.2% during the 1st quarter. DLD Asset Management LP now owns 172,867 shares of the company’s stock worth $688,000 after purchasing an additional 14,635 shares during the period. CSS LLC IL acquired a new stake in shares of Ayala Pharmaceuticals during the 4th quarter worth approximately $131,000. Finally, Marshall Wace LLP acquired a new stake in shares of Ayala Pharmaceuticals during the 4th quarter worth approximately $420,000. 56.07% of the stock is currently owned by institutional investors.

A number of analysts have commented on AYLA shares. Zacks Investment Research downgraded Ayala Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, April 1st. Raymond James decreased their target price on Ayala Pharmaceuticals from $24.00 to $6.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 30th. Oppenheimer decreased their target price on Ayala Pharmaceuticals from $25.00 to $16.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 30th. Finally, Maxim Group decreased their target price on Ayala Pharmaceuticals from $22.00 to $12.00 in a research report on Wednesday, March 30th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $16.63.

About Ayala Pharmaceuticals (Get Rating)

Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.

See Also

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.